Tisotumab vedotin (HuMax®-TF-ADC) is an antibody-drug conjugate (ADC) targeted to Tissue Factor (TF), a protein involved in tumor signaling and angiogenesis. Based on its high expression on many solid tumors and its rapid internalization, TF is a suitable target for an ADC approach. Tisotumab vedotin has shown strong ability to bind to TF and inhibit tumor growth in pre-clinical experiments. Genmab has entered a collaboration for Tisotumab vedotin with Seattle Genetics. Tisotumab vedotin is in Phase I trials to treat multiple solid tumors.
Back to top
Tisotumab vedotin is being tested in 8 solid tumors (ovary, cervix, endometrium, bladder, prostate, head & neck, esophagus, lung). For more information on these studies, visit clinicaltrials.gov.